Characteristics | Secondary drug resistance rate | Change | ||||
---|---|---|---|---|---|---|
2016 n = 81 | 2017 n = 51 | 2018 n = 51 | 2019 n = 41 | 2020 n = 22 | 856.23 | |
DR-TB (Total) | 5 (6.17) | 8 (15.6) | 10 (19.6) | 14 (34.1) | 13 (59) | |
Type | ||||||
MR-TB | 1 (1.2) | 1 (1.9) | 2 (3.9) | 0 | 1 (4.5) | 275 |
MDR-TB | 3 (3.7) | 6 (11.7) | 3 (5.8) | 12 (29.2) | 11 (50) | 1 251.35 |
PDR-TB | 1 (1.2) | 1 (1.9) | 5 (9.8) | 2 (4.8) | 1 (4.5) | 275 |
Age (years) | ||||||
≤ 14 | 0 | 0 | 0 | 0 | 0 | 0 |
15–34 | 2 (8.6) | 3 (30) | 4 (21) | 6 (40) | 4 (44.4) | 416.27 |
35–54 | 1 (4) | 2 (12.5) | 4 (26.6) | 4 (30.7) | 7 (87.5) | 2 087.5 |
≥ 55 | 2 (6.6) | 3 (13) | 2 (11.7) | 4 (30.7) | 2 (40) | 506.06 |
Sex | ||||||
Female | 2 (4.7) | 3 (15.7) | 4 (13.3) | 11 (45.8) | 5 (62.5) | 1129.78 |
Male | 3 (7.6) | 5 (15.6) | 6 (28.5) | 3 (17.6) | 8 (57.1) | 651.31 |
First-line drugs | ||||||
INH | 4 (4.9) | 6 (11.8) | 6 (11.8) | 14 (34) | 12 (54.5) | 10.12 |
RIF | 4 (4.9) | 6 (11.8) | 5 (9.8) | 12 (29.3) | 12 (54.5) | 10.12 |
EMB | 1 (1.2) | 4 (7.8) | 5 (9.8) | 5 (12.2) | 6 (27.3) | 21.75 |
SM | 1 (1.2) | 5 (9.8) | 5 (9.8) | 7 (17) | 6 (27.3) | 21.75 |
Characteristics | Primary drug resistance rate | Change | ||||
---|---|---|---|---|---|---|
*2016 n = 512 | 2017 n = 584 | 2018 n = 490 | 2019 n = 410 | 2020 n = 300 | 204.54 | |
DR-TB (Total) | 1 (0.1) | 13 (2.2) | 5 (1) | 15 (3) | 20 (6.7) | |
Type | ||||||
MR-TB | 0 | 5 (0.85) | 2 (0.4) | 9 (2) | 12 (4) | 370.58 |
MDR-TB | 0 | 1 (0.17) | 1 (0.2) | 1 (0.2) | 5 (1.6) | 841.17 |
PDR-TB | 1 (0.1) | 7 (1.19) | 2 (0.4) | 5 (1.2) | 3 (1) | –15.96 |
Age (years) | ||||||
≤ 14 | 0 | 1 (1.6) | 0 | 0 | 1 (3.1) | 93.75 |
15–34 | 1 (0.6) | 4 (1.9) | 2 (1.08) | 6 (4.1) | 8 (7.1) | 273.68 |
35–54 | 0 | 4 (2.58) | 2 (1.45) | 2 (1.63) | 6 (7.14) | 176.74 |
≥ 55 | 0 | 4 (2.54) | 1 (0.85) | 7 (7.2) | 5 (7.04) | 177.16 |
Sex | ||||||
Female | 1 (0.46) | 5 (1.75) | 3 (1.2) | 10 (4.9) | 10 (8.13) | 364.57 |
Male | 0 | 8 (2.67) | 2 (0.8) | 5 (2.4) | 10 (5.64) | 111.23 |
First-line drugs | ||||||
INH | 1 (0.19) | 5 (0.85) | 3 (0.61) | 8 (1.95) | 6 (2) | 1.35 |
RIF | 0 | 1 (0.17) | 2 (0.4) | 3 (0.73) | 12 (4) | 22.5 |
EMB | 0 | 6 (1) | 1 (0.2) | 5 (1.21) | 1 (0.3) | –0.7 |
SM | 1 (0.19) | 11 (1.9) | 2 (0.4) | 5 (1.21) | 11 (3.7) | 18.47 |
Drug resistance | New cases n = 2296 (%) | Retreated cases n = 246 (%) | |
---|---|---|---|
DR-TB | 54 (2.4) | 50 (20.3) | 0.0001 |
Any resistance to first-line drugs | |||
INH | 23 (1) | 42(17.1) | 0.0001 |
RIF | 18 (0.78) | 39 (15.8) | 0.0001 |
EMB | 13 (0.56) | 21 (8.5) | 0.011 |
SM | 30 (1.3) | 24 (9.75) | 0.007 |
MR-TB (Total) | 28 (1.22) | 5 (2) | 0.564 |
INH | 4 (0.17) | 0 | 0.102 |
RIF | 7 (0.3) | 3 (1.2) | 0.206 |
EMB | 4 (0.17) | 1 (0.4) | 0.180 |
SM | 13 (0.56) | 1 (0.4) | 0.001 |
MDR-TB (Total) | 8 (0.34) | 35 (14.2) | 0.0001 |
MDR1: INH + RIF | 7 (0.3) | 20 (8.1) | 0.011 |
MDR2: INH + RIF +EMB | 0 | 2 (0.81) | 0.317 |
MDR3: INH + RIF + EMB + SM | 1 (0.04) | 12 (4.8) | 0.002 |
MDR4: INH + RIF + SM | 0 | 1 (0.4) | 0.564 |
PDR-TB (Total) | 18 (0.78) | 10 (4.1) | 0.257 |
PDR1: INH + EMB | 2 (0.08) | 0 | 1.000 |
PDR2: INH + SM | 7 (0.3) | 3 (1.2) | 0.564 |
PDR3: RIF + EMB | 0 | 0 | – |
PDR4: RIF + SM | 3 (0.13) | 1 (0.4) | 1.000 |
PDR5: INH + EMB + SM | 2 (0.08) | 4 (1.6) | 0.317 |
Others (SM + EMB) | 4 (0.17) | 2 (0.81) | 0.564 |
New cases | Retreated cases | New cases vs. Retreated cases | Primary DR-TB vs. Acquired DR | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Total n = 2296 | DR-TB n = 54 (2.4) | Susceptible TB n = 2242 (97.6) | OR (95% CI) | p-value | Total n = 246 | DR-TB n = 50 (20.3) | Susceptible TBn=196 (79.7) | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value |
Age | ||||||||||||||
< 14 | 254 | 2 | 252 | 0.233 | 0.051 | 5 | 0 | 5 | 0.431 | 0.576 | 7.748 | <0.0001 | 3.974 | 0.384 |
(11) | (3.7) | (11.23) | (0.054-1.008) | (2) | (2.6) | (0.023-8.207) | (3.109-19.308) | (0.178-89.003) | ||||||
15-34 | 804 | 21 | 783 | 0.788 | 0.458 | 76 | 19 | 57 | 1.622 | 0.212 | 1.613 | 0.004 | 0.873 | 0.771 |
(35) | (38.9) | (34.9) | (0.420-1.479) | (30.8) | (38) | (29.1) | (0.758-3.470) | (1.166-2.233) | (0.348-2.186) | |||||
35-54 | 661 | 12 | 649 | 0.543 | 0.102 | 77 | 16 | 61 | 1.277 | 0.541 | 1.309 | 0.105 | 0.592 | 0.308 |
(28.7) | (22.2) | (28.9) | (0.261-1.129) | (31.3) | (32) | (31.12) | (0.584-2.791) | (0.945-1.813) | (0.216-1.624) | |||||
>55 | 577 | 19 | 558 | Ref. | Ref. | 88 | 15 | 73 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(25.1) | (35.2) | (24.9) | (35.7) | (30) | (37.2) | |||||||||
Sex | ||||||||||||||
Female | 1076 | 29 | 1047 | 1.324 | 0.310 | 123 | 25 | 98 | 1.000 | 1.000 | 0.882 | 0.349 | 1.16 | 0.706 |
(46.8) | (53.7) | (46.7) | (0.771-2.275) | (50) | (50) | (50) | (0.537-1.861) | (0.678-1.147) | (0.537-2.506) | |||||
Male | 1220 | 25 | 1195 | Ref. | Ref. | 123 | 25 | 98 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref |
(53.1) | (46.3) | (53.3) | (50) | (50) | (50). | |||||||||
Smoking | ||||||||||||||
Yes | 580 | 13 | 567 | 0.937 | 0.839 | 70 | 15 | 55 | 1.099 | 0.786 | 0.850 | 0.276 | 0.740 | 0.497 |
(25.3) | (24.1) | (25.3) | (0.498-1.761) | (28.4) | (30) | (28.1) | (0.556-2.170) | (0.634-1.139) | (0.310-1.764) | |||||
No | 1716 | 41 | 1675 | Ref. | Ref. | 176 | 35 | 141 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(74.7) | (75.9) | (74.7) | (71.5) | (70) | (71.9) | |||||||||
Cavity | ||||||||||||||
Yes | 710 | 32 | 678 | 1.018 | 0.950 | 153 | 39 | 114 | 0.958 | 0.917 | 0.372 | <0.0001 | 0.391 | 0.038 |
(30.9) | (59.6) | (30.6) | (0.580-1.788) | (62.1) | (78) | (58.2) | (0.428-2.150) | (0.256-0.541) | (0.161-0.948) | |||||
No | 474 | 21 | 453 | Ref. | Ref. | 38 | 1 | 28 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(20.6) | (38.9) | (20.2) | (15.4) | (20) | (14.3) | |||||||||
Infiltration | ||||||||||||||
Yes | 308 | 13 | 295 | 0.921 | 0.801 | 50 | 13 | 37 | 1.025 | 0.948 | 0.992 | 0.962 | 0.9 | 0.817 |
(13.4) | (24.1) | (13.2) | (0.486-1.746) | (20.3) | (26) | (18.9) | (0.490-2.140) | (0.700-1.404) | (0.369-2.194) | |||||
No | 876 | 4 | 836 | Ref. | Ref. | 141 | 36 | 105 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(38.1) | (74.1) | (37.3) | (57.3) | (72) | (53.6) | |||||||||
Other abnormalities | ||||||||||||||
Yes | 142 | 6 | 136 | 0.934 | 0.878 | 23 | 6 | 17 | 1.026 | 0.960 | 0.995 | 0.985 | 0.915 | 0.885 |
(6.1) | (11.1) | (6.04) | (0.392-2.226) | (9.3) | (12) | (8.7) | (0.380-2.770) | (0.622-1.592) | (0.274-3.052) | |||||
No | 1042 | 47 | 995 | Ref. | Ref. | 168 | 43 | 125 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(45.3) | (87) | (44.4) | (68.2) | (86) | (63.8) | |||||||||
Clear | ||||||||||||||
Yes | 4 | 1 | 3 | 7.23 | 0.089 | 0 | 0 | 0 | 2.879 | 0.598 | 1.46 | 0.800 | 2.829 | 0.527 |
(0.17) | (1.9) | (0.13) | (0.739-70.71) | (0.056-147.03) | (0.078-27.227) | (0.113-71.087) | ||||||||
No | 118 | 52 | 1128 | Ref. | Ref. | 191 | 49 | 142 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(51.3) | (96.3) | (50.3) | (77.6) | (98) | (72.4) | |||||||||
Type | ||||||||||||||
Extra | 1112 | 1 | 1111 | Ref. | Ref. | 55 | 1 | 54 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
pulmonary TB | (48.4) | (1.9) | (49.6) | (22.3) | (2) | (27.6) | ||||||||
Pulmonary TB | 118 | 53 | 1131 | 52.062 | 0.0001 | 191 | 49 | 142 | 18.634 | 0.004 | 0.307 | <0.0001 | 1.082 | 0.956 |
(51.5) | (98.1) | (50.4) | (7.19-377.13) | (77.6) | (98) | (72.4) | (2.51-138.31) | (0.225-0.418) | (0.066-17.768) | |||||
Region | ||||||||||||||
Urban | 993 | 32 | 961 | 1.939 | 0.018 | 87 | 27 | 60 | 2.661 | 0.003 | 1.393 | 0.018 | 1.239 | 0.589 |
(43.2) | (59.3) | (42.9) | (1.12-3.358) | (35.3) | (54) | (30.6) | (1.412-5.015) | (1.059-1.832) | (0.570-2.965) | |||||
Rural | 1303 | 2 | 1281 | Ref. | Ref. | 159 | 23 | 136 | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. |
(56.7) | (40.7) | (57.1) | (64.6) | (46) | (69.4) |